Featured Research

from universities, journals, and other organizations

University Of Washington Discovery May Point The Way To New Treatment For Hepatitis C Cases That Do Not Respond To Interferon Therapy

Date:
April 15, 1997
Source:
University of Washington
Summary:
Researchers at the University of Washington report in the April 14, 1997 issue of Virology that they may have an explanation for why the currently approved drug treatment for hepatitis C, interferon, is ineffective much of the time.

Researchers at the University of Washington report in the April 14, 1997 issue of Virology that they may have an explanation for why the currently approved drug treatment for hepatitis C is ineffective much of the time. The drug, recombinant alpha interferon, is ineffective in 60 to 80 percent of cases.

"This discovery explains the molecular mechanisms for interferon resistance, and points the way to a potential new target for therapeutic drugs to treat hepatitis C," said the principal investigator, Dr. Michael G. Katze (kates), UW professor of microbiology and associate director of the UW's Regional Primate Research Center.

The UW's Office of Technology Transfer has negotiated a patent-based licensing agreement with RiboGene, Inc., a privately-held biotechnology company in Hayward, Calif., which will begin investigating drug therapies based on the UW discovery. Katze is a member of the company's scientific advisory board.

Hepatitis C (formerly called non-A, non-B hepatitis), caused by the virus, affects more than 3.5 million Americans. It is the major reason for liver failure necessitating liver transplants.

"Many viruses that affect humans -- hepatitis, influenza, herpes, HIV, polio and a host of others -- have evolved mechanisms to resist the effects of interferon, one of the body's first lines of defense against viruses," said Dr. Michael Gale, Jr., UW microbiology fellow who is lead scientist and first author of the study. The drug interferon is an artificial version of naturally-occurring interferon, a protein secreted by cells that "interferes with" viral infection and other challenges.

Earlier studies in Japan showed that interferon-resistant HCV strains have a specific RNA sequence within a region of the virus called NS5A. The UW researchers followed up on this research, and tested the ability of NS5A to interact with a key component of interferon response called PKR, a member of an important family of enzymes called protein kinases.

Katze and his team found that the NS5A protein in two strains of HCV -- one found mainly in the United States, the other in Asia -- had the ability to bind to and inactivate PKR. "This has strong implications," said Gale. "We have shown that PKR is important in the interferon response."

"We believe we've identified a potential target for therapeutics," said Katze. "If a compound can be identified that inhibits or prevents the association of NS5A with PKR without affecting PKR's ability to function, interferon response could be restored. If the compound were administered in combination with interferon, it could potentially bring the virus under control and allow the body's immune system to knock it out." Katze cautions that while his team's research is an important first step, a therapy for HCV is not around the corner.

The study is published in the April 14 edition of Virology (vol. 230, no. 2, pp. 217-227, Academic Press) and funded by the National Institutes of Health. Co-authors are Drs. Marcus J. Korth, Norina M. Tang, Seng-Lai Tan, Deborah A. Hopkins, Stephen J. Polyak and David R. Gretch, all of the University of Washington; and Thomas E. Dever of the National Institute of Child Health and Human Development.

Facts about Hepatitis C

Up to 3.5 million Americans are believed chronically infected with the hepatitis C virus, formerly called non-A, non-B hepatitis. Some 20 to 40 percent of people coming to inner-city hospitals have the virus, as do about 80 percent of intravenous drug users. While hepatitis C is transmitted through blood and shared needles, studies have shown that about 40 percent of carriers do not report such risk factors. The nation's blood supply has been tested for hepatitis C since 1990.The disease causes symptoms such as fatigue, nausea, loss of appetite, dark urine and jaundice, but up to 70 percent of patients lack symptoms in the early stages. Infected individuals usually are unaware of their disease until they develop serious complications. The disease may occur in the acute form and be followed by recovery, or it may become chronic and cause symptoms for years.The federal Centers for Disease Control and Prevention (CDC) estimates that 20 to 50 percent of chronically infected hepatitis C patients will develop cirrhosis of the liver, and 20 to 30 percent of those will develop liver cancer or liver failure requiring transplant.There are an estimated 150,000 to 250,000 new cases of hepatitis C infection each year in the U.S., and the disease contributes to the death of more than 12,000 American annually; this toll is expected to triple by the year 2010, according to the CDC.

###


Story Source:

The above story is based on materials provided by University of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University of Washington. "University Of Washington Discovery May Point The Way To New Treatment For Hepatitis C Cases That Do Not Respond To Interferon Therapy." ScienceDaily. ScienceDaily, 15 April 1997. <www.sciencedaily.com/releases/1997/04/970415113913.htm>.
University of Washington. (1997, April 15). University Of Washington Discovery May Point The Way To New Treatment For Hepatitis C Cases That Do Not Respond To Interferon Therapy. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/1997/04/970415113913.htm
University of Washington. "University Of Washington Discovery May Point The Way To New Treatment For Hepatitis C Cases That Do Not Respond To Interferon Therapy." ScienceDaily. www.sciencedaily.com/releases/1997/04/970415113913.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins